Previsión
El precio objetivo medio de los analistas es de 12,87 € (+25,32 %). La mediana es de 13,20 € (+28,53 %).
| Comprar |
9 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Cellebrite plans to relocate corporate headquarters from Israel to the US
Cellebrite’s board has approved a restructuring that would place a new US parent company at the top of the group’s corporate structure. The move is subject to shareholder and regulatory approval and is expected to be completed by H1 2027. CEO Shiv Ramji cites growth in key markets, greater attractiveness to investors and possible index inclusion as reasons; further details will be disclosed via SEC filings. » Más en de.investing.com
Cellebrite brings AI tool Genesis to enterprises and expands international availability
Cellebrite is making its AI-powered investigation tool Genesis generally available to enterprises and is expanding the market to countries such as Australia, the United Kingdom and soon the EU. Genesis, which has already been used by law enforcement since June 2026, is now intended for internal investigations such as employee misconduct, financial fraud, M&A due diligence, insider threats and compliance. At the same time, the company is introducing the Deep Investigator feature to extract hard-to-access mobile data and plans to add additional features and data sources in the coming months. » Más en de.investing.com
Cellebrite DI: 30% sell-off as entry opportunity, JPMorgan sees over 40% potential
Cellebrite DI was punished by more than 30% at times after the Q2 results and the surprise CEO change, but is being viewed as a buying opportunity. Criticisms include longer sales cycles and slower monetization progress on product updates, while the core story remains intact according to the report. JPMorgan sees more than 40% upside; the price-to-sales (P/S) ratio is below 5 after the pullback and Shiven Ramji takes over the CEO role immediately. » Más en finanzen.net
Cellebrite DI falls to 52-week low despite strong metrics
Cellebrite DI shares fell to 10.01 USD, reaching a new 52-week low, despite a roughly 9% gain over the past 12 months. Analysts at InvestingPro currently view the stock as undervalued with significant upside potential. The company reports high gross profit margins of 83.9% and more cash than debt, and beat expectations in Q1 2026 with EPS of 0.12 USD; revenue was 128.3 million USD. TD Cowen reaffirmed its buy rating and set a price target of 23 USD. » Más en de.investing.com
Cellebrite technology used by Russia to extract data from opposition iPhone after sales ban
University of Toronto’s Citizen Lab and legal records show Russian investigators used Cellebrite’s UFED to access opposition politician Andrey Pivovarov’s iPhone in June 2021, months after Cellebrite said it stopped sales to Russia. Evidence suggests the device extracted contacts and messages tied to Open Russia and contributed to subsequent surveillance and phishing operations against dissidents. Cellebrite says post‑March 2021 use is unauthorized and legacy hardware would lack support, while critics call for stronger legal and technical controls including a killswitch. » Más en forbes.com
Datos financieros
En el último trimestre, CELLEBRITE DI LTD tuvo unos ingresos de 131,56 M € y un beneficio neto de 23,53 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 131,56 M | 22,51 % |
| Beneficio bruto | 106,87 M | 18,63 % |
| Beneficio neto | 23,53 M | 36,79 % |
| EBITDA | 31,97 M | 39,01 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 2554,24 M € |
Número de acciones | 251,34 M |
Máximo/mínimo de 52 semanas | 17,66 € - 8,72 € |
| Dividendos | No |
Beta | 1,05 |
Ratio P/E | 42,18 |
Ratio PEG | -2,61 |
Ratio P/B | 5,14 |
Ratio P/S | 5,22 |
Perfil de la empresa
Cellebrite DI Ltd. desarrolla soluciones para investigaciones autorizadas legalmente. Su plataforma DI permite a los usuarios recopilar, revisar, analizar y gestionar datos digitales a lo largo del ciclo de vida de la investigación en relación con investigaciones autorizadas legalmente, y las soluciones se utilizan en diversos casos, incluidos la explotación infantil, el homicidio, la lucha antiterrorista, el control fronterizo, los delitos sexuales, la trata de personas, la seguridad corporativa, el robo de propiedad intelectual y los litigios civiles. La solución Universal Forensic Extraction Device de la empresa aborda los problemas de acceso a la información digital, incluidos los bloqueos complejos de dispositivos, las barreras de cifrado, el contenido eliminado y desconocido, y otros obstáculos que pueden impedir que pruebas fundamentales salgan a la luz. También ofrece la solución Seeker, que permite analizar grabaciones de vídeo; OSINT Analyze, una solución de análisis en profundidad en tiempo real utilizada para analizar información de fuentes abiertas, como la web superficial, la web profunda y la dark web; y Crypto Tracer, que analiza transacciones de blockchain junto con datos relacionados de una amplia lista de fuentes para identificar y categorizar carteras y transacciones. La empresa atiende a agencias federales, estatales y locales, así como a empresas corporativas y proveedores de servicios. Tiene operaciones en Estados Unidos, Alemania, Singapur, Australia, Brasil, Reino Unido, Francia, Canadá, Japón e India. La empresa se constituyó en 1999 y tiene su sede en Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. opera como filial de Sun Corporation.
| Nombre | CELLEBRITE DI LTD |
| CEO | Shiv Ramji |
| Sede | Petah Tikva,
hm Israel |
| Sitio web | |
| Industria | Tecnología sanitaria |
| Salida a bolsa | 06/11/2020 |
| Empleados | 1285 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | CLBT |